| 1 |
34137279 | Potential Dexamethasone-Direct Oral Anticoagulant Drug Interaction: Is This a Concern in COVID? | 2022 Mar |
1 |
| 2 |
35174529 | Tyrosine kinase inhibitors and direct oral anticoagulants: In vitro evaluation of drug-drug interaction mediated by P-glycoprotein. | 2022 Feb 16 |
2 |
| 3 |
32329770 | Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney Function. | 2020 Apr 1 |
1 |
| 4 |
32862668 | Drug-Drug Interactions of 257 Antineoplastic and Supportive Care Agents With 7 Anticoagulants: A Comprehensive Review of Interactions and Mechanisms. | 2020 Jan-Dec |
1 |
| 5 |
31113643 | Indications and potential pitfalls of anticoagulants in pulmonary hypertension: Would DOACs become a better option than VKAs? | 2019 Sep |
1 |
| 6 |
31520256 | Impact of Polypharmacy and P-Glycoprotein- and CYP3A4-Modulating Drugs on Safety and Efficacy of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation. | 2019 Oct |
1 |
| 7 |
28895074 | In Vitro Comparison of the Role of P-Glycoprotein and Breast Cancer Resistance Protein on Direct Oral Anticoagulants Disposition. | 2018 Apr |
2 |
| 8 |
29274758 | Efficacy and Safety Outcomes of Direct Oral Anticoagulants and Amiodarone in Patients with Atrial Fibrillation. | 2018 May |
2 |
| 9 |
29572341 | In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein. | 2018 Jun |
3 |
| 10 |
27893182 | Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. | 2017 Feb |
3 |